<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03960385</url>
  </required_header>
  <id_info>
    <org_study_id>DNG10042</org_study_id>
    <nct_id>NCT03960385</nct_id>
  </id_info>
  <brief_title>Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil</brief_title>
  <official_title>Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert B. Sabin Vaccine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pan American Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State of Parana/Health Department of Parana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health of Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Estudos Augusto Leopoldo Ayrosa Galvão</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert B. Sabin Vaccine Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study seeks to assess the effectiveness of Sanofi Pasteur´s dengue vaccine (Dengvaxia®)&#xD;
      according to the age, dose and municipality of residence in five municipalities of Paraná&#xD;
      State. Specific objectives include:&#xD;
&#xD;
        -  To assess the effectiveness of Dengvaxia® in preventing dengue hospitalization and&#xD;
           dengue symptomatic cases.&#xD;
&#xD;
        -  To assess the effectiveness of Dengvaxia® in preventing dengue hospitalization and&#xD;
           dengue symptomatic cases according in the following age groups 15 to 18 and 19 to 27&#xD;
           years of age in the municipalities of Maringá, Foz de Iguaçu, Londrina, Sarandi and&#xD;
           Paranaguá.&#xD;
&#xD;
        -  To assess the effectiveness of Dengvaxia® in preventing dengue hospitalization and&#xD;
           dengue symptomatic cases in the following age groups 9 to 14 and 28 to 45 years of age&#xD;
           in the municipality of Paranaguá.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effectiveness of Sanofi Pasteur´s dengue vaccine (Dengvaxia®) according to the age will&#xD;
      be assessed in five municipalities of Paraná State - Maringá, Foz de Iguaçu, Londrina,&#xD;
      Sarandi and Paranaguá. Any health service located in each of the five municipalities may&#xD;
      report a suspected dengue case. However, in all five municipalities, there is a large public&#xD;
      emergency service, the UPA. There are currently three UPA in Londrina, two in Maringá and Foz&#xD;
      do Iguaҫu and one each in Paranaguá and Sarandi. These facilities are responsible for&#xD;
      reporting the majority of suspected dengue cases. In Londrina and Maringá, the private health&#xD;
      sector also provides emergency care. The implementation of the study protocol adds a&#xD;
      collection of a blood sample for PCR to the existing protocol for addressing suspected dengue&#xD;
      cases among individuals within the target vaccination age groups.&#xD;
&#xD;
      The study will count on the activities already carried out by teams of epidemiological&#xD;
      surveillance of dengue intensifying the identification of the serotype through the laboratory&#xD;
      method RT-PCR (Reverse Transcription Polymerase Chain Reaction) in real time. In addition,&#xD;
      the investigators will identify hospitals and health units that attend dengue cases for&#xD;
      sample collection, to perform real-time RT-PCR and initial processing of the blood samples&#xD;
      collected from the controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dengue symptomatic case</measure>
    <time_frame>Aug 2017 - March 2020</time_frame>
    <description>Confirmed (by PCR) case of dengue fever</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dengue hospitalization</measure>
    <time_frame>Aug 2017 - March 2020</time_frame>
    <description>Hospitalization for severe dengue fever</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1854</enrollment>
  <condition>Dengue</condition>
  <arm_group>
    <arm_group_label>Hospitalized and controls</arm_group_label>
    <description>Age-matched case of hospitalized dengue and non-dengue control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Outpatient and controls</arm_group_label>
    <description>Age-matched dengue case and non-dengue control</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYD-TDV</intervention_name>
    <description>Dengue vaccine</description>
    <arm_group_label>Hospitalized and controls</arm_group_label>
    <arm_group_label>Outpatient and controls</arm_group_label>
    <other_name>Dengvaxia®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The effectiveness of Sanofi Pasteur´s dengue vaccine (Dengvaxia®) according to age will be&#xD;
        assessed in 5 municipalities of Paraná State - Maringá, Foz de Iguaçu, Londrina, Sarandi&#xD;
        and Paranaguá. The municipalities were chosen because they are of medium size and have a&#xD;
        history of dengue. The first 4 present a historical series of occurrence of dengue since&#xD;
        the 1990s, while in Paranaguá the history of the disease is more recent. Any health service&#xD;
        located in each of the five municipalities may report a suspected dengue case. In all five&#xD;
        municipalities, there is a large public emergency service, the UPA, which is responsible&#xD;
        for reporting the majority of suspected dengue cases. In Londrina and Maringá, the private&#xD;
        health sector also provides emergency care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria for cases:&#xD;
&#xD;
          -  Individuals living in the municipalities of Sarandi, Paranaguá, Londrina, Maringá or&#xD;
             Foz de Iguaçu in the three stages of vaccination&#xD;
&#xD;
          -  Individuals with ages ranging from 9 to 44 years for the municipality of Paranaguá and&#xD;
             15 to 27 years for the municipalities of Sarandi, Londrina, Maringá and Foz de Iguaçu&#xD;
&#xD;
          -  All participants who are 18 years of age or older sign the informed consent form&#xD;
&#xD;
          -  All minors under the age of 18 who sign the consent form and have the consent form&#xD;
             signed by a guardian for the minor&#xD;
&#xD;
          -  Case with virological isolation of one of the dengue viruses&#xD;
&#xD;
        Case exclusion criteria:&#xD;
&#xD;
        • Those who have been deprived of their liberty (jails, penitentiaries, drug addicts, etc.)&#xD;
        within 15 days before the onset of signs and symptoms&#xD;
&#xD;
        Inclusion criteria for controls:&#xD;
&#xD;
          -  Individuals without symptoms for dengue in the 15 days prior to the onset of symptoms&#xD;
             of the case&#xD;
&#xD;
          -  IgM negative for dengue&#xD;
&#xD;
          -  Individuals living in the municipalities of Paranaguá, Londrina, Maringá, Sarandi or&#xD;
             Foz de Iguaçu in the three stages of vaccination&#xD;
&#xD;
          -  Belongs to the same age group as case&#xD;
&#xD;
          -  Participants aged between 9 and 44 years for the municipality of Paranaguá&#xD;
&#xD;
          -  Participants 15 to 27 years for the municipalities of Maringá, Foz de Iguaçu, Londrina&#xD;
             and Sarandi&#xD;
&#xD;
          -  Resides in the same neighborhood as the case, study at the same institution as the&#xD;
             case or work in the same company as the case for at least 15 days before the onset of&#xD;
             the case symptoms&#xD;
&#xD;
          -  Participants that are 18 years of age or older and who sign the informed consent form&#xD;
&#xD;
          -  All minors under the age of 18 who sign the consent form and have the consent form&#xD;
             signed by a guardian for the minor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise O Garrett, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Albert B. Sabin Vaccine Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Augusto Leopoldo Ayrosa Galvão Study Center</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dengue</keyword>
  <keyword>Dengvaxia</keyword>
  <keyword>Parana</keyword>
  <keyword>Sanofi Pasteur</keyword>
  <keyword>Vaccine Effectiveness</keyword>
  <keyword>Maringa</keyword>
  <keyword>Foz de Iguacu</keyword>
  <keyword>Paranagua</keyword>
  <keyword>Brazil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

